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CObjectives: To evaluate the association between hypoglycemia and
health-related quality of life (HRQoL) in the context of a clinical trial
using both an objectively confirmed and a patient-reportedmeasure of
hypoglycemia. Methods: During a phase III, double-arm, randomized
tudy, patients completed the short form 36 health survey (SF-36), a
eneric HRQoL questionnaire, at baseline and at weeks 24, 52, and 104.
he objectively confirmed measure of hypoglycemia was based on a
ombination of plasma glucose measure and presence of hypoglyce-
ia-related symptoms. The patient-reported frequency of hypoglyce-
ia was defined as the following item: “How often have you felt that
our blood sugars have been unacceptably low recently?” The associ-
tion between hypoglycemia and HRQoL was evaluated in intent-to-
reat patients (N  3059) by using repeated-measurements analyses,
ith SF-36 scores used as explained variables and baseline SF-36
core, age, sex, country, time, and either number of objectively con-
rmed hypoglycemic events (0, 1) or patient-reported frequency of O
ue d
ty fo
http://dx.doi.org/10.1016/j.jval.2012.06.002ypoglycemia (continuous variable 0–6) as explanatory variables.
esults: During study duration, less than 6%of patients experienced at
east one objectively confirmed hypoglycemic event and about half the
atients reported unacceptably low blood sugars “none of the time.”
he association between the number of objectively confirmed hypogly-
emic events and HRQoL was not statistically significant, while the
atient-reported frequency of hypoglycemia was statistically signifi-
antly related to all SF-36 scores (P  0.001), except physical function-
ng; patients reporting greater perceived frequency of hypoglycemia
ad worse HRQoL. Conclusions: Using a patient-reported measure of
ypoglycemia in the context of a clinical trial could enable the burden
f hypoglycemia for patients to be demonstrated.
eywords: clinical trial, diabetes, health-related quality of life, hypogly-
emia, measurement.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Type 2 diabetes is a chronic, progressive disease characterized by
hyperglycemia resulting from multiple abnormalities including
impaired insulin secretion and peripheral insulin resistance. Type
2 diabetes is associated with serious long-term microvascular
and macrovascular complications such as cardiovascular dis-
ease, neuropathy, and diseases of the eyes, which, in turn, in-
crease morbidity, mortality, and health care costs [1–4]. Treat-
ents can include oral medications for hyperglycemia and for
ther conditions often associated with diabetes such as hyper-
ension and dyslipidemia, or insulin therapy. However, treat-
ents require above all a lifelong commitment of patients to
lood sugar monitoring, healthy eating, regular physical exer-
ise, and weight control, thus making diabetes management
ery restrictive. In addition, certain diabetes treatments are as-
ociated with side effects such as hypoglycemia and weight
ain [5,6]. In particular, sulfonylureas are typically known to
ause hypoglycemia, with older sulfonylureas such as glyburide
ssociated with a higher risk of events [7,8]. Hypoglycemia can
be a major barrier in achieving treatment goals and has been
shown to be linked to an increased risk of cardiovascular events
* Address correspondence to: Hélène Gilet, Mapi Consultancy, 27 r
E-mail: hgilet@mapigroup.com.
1098-3015 – see front matter Copyright © 2012, International Socie
Published by Elsevier Inc.[9] and dementia [10] and by “defensive eating” can contribute
to weight gain [11].
Even though it is agreed that a hypoglycemic event should be
characterized by a combination of a symptomatic episode and the
measure of plasma glucose, defining hypoglycemic events re-
mains difficult as no consensus exists on the plasma glucose
threshold to be used. For the EMA, a symptomatic episode with
plasma glucose level lower than 54 mg/dL (3 mmol/L) can be qual-
ified as a hypoglycemic event [12], while for the Food and Drug
Administration (FDA), a hypoglycemic event is defined as an event
combining typical symptoms of hypoglycemia andplasma glucose
level lower than 70mg/dL (3.9mmol/L) [13]. In addition, the report-
ing of hypoglycemic events is challenging not only because of hy-
poglycemia unawareness [14] but also because patients often do
notmeasure their blood glucose level on a regular basis [15,16] and
hypoglycemic events commonly occur during the night when the
patient is not aware of them [17,18]. Thus, only a small proportion
of the true hypoglycemic events can be captured.
In observational studies, a wide range of any hypoglycemic
event rates were observed: 38% in the Real-Life Effectiveness and
Care Patterns of Diabetes Management study in patients with a
sulfonylurea or thiazolidinedione added to ongoing metformin
therapy [19], 63% in a US Internet-based survey in patients taking
e la Villette, 69003 Lyon, France.
r Pharmacoeconomics and Outcomes Research (ISPOR).
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1037V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 3 6 – 1 0 4 1oral antihyperglycemic medications [20], and between 10% and
28% in the first decade of the UK Prospective Diabetes Study in
patients treated with diet alone and insulin, respectively [21]. In
randomized clinical trials, rates of any hypoglycemic events
were 10% for patients treated with rosiglitazone compared with
12% for patients treated with metformin and 39% for patients
treated with glyburide in A Diabetes Outcomes Progression Trial
[22], and 28% for patients treated with pioglitazone compared
with 20% for placebo in the PROspective pioglitAzone Clinical
Trial in macroVascular Events study [23]. Establishing one esti-
ation of the incidence of hypoglycemia based on the litera-
ure, however, is not feasible because of a wide variety in the
efinitions of hypoglycemia, type of study, type of treatment,
nd characteristics of the population used in studies reporting
ypoglycemic event rates [24].
Because diabetes patients face many issues related to the dis-
ase and its treatment, separating the direct benefit of the treat-
ent on patients’ health-related quality of life (HRQoL) from all
ther elements involved is often challenging in clinical trials de-
pite improvements on primary clinical outcomes [25–28]. The
articular impact of hypoglycemia on HRQoL has often been dem-
nstrated in observational studies [20,29–33], suggesting that the
otential indirect benefit of a diabetes treatment on HRQoL could
e demonstrated through the burden of hypoglycemia. Random-
zed clinical trials, however, generally focus only on the direct
mpact of a treatment on HRQoL, and it is not clear whether the
mpact of hypoglycemia on HRQoL demonstrated in observa-
ional studies could be shown in the monitored context of a
andomized clinical trial. The objective of this study was to
valuate the association between hypoglycemia and HRQoL in
he context of a clinical trial using different measures of hypo-
lycemia, including both objectively confirmed and patient-re-
orted measures of hypoglycemia.
Methods
Study design
The CLAF237-2308 studywas a phase III, double-arm,multicenter,
randomized, double-blind, active controlled study evaluating the
long-term efficacy of treatment with vildagliptin as add-on ther-
apy compared with glimepiride in patients with type 2 diabetes
inadequately controlled with metformin monotherapy. Patients
included were diagnosed with type 2 diabetes, male or female,
aged between 18 and 73 years, had a hemoglobin A1c (HbA1c) level
igher than 6.5% and lower than or equal to 8.5%, and were inad-
quately controlled withmetformin. In this study, vildagliptin has
emonstrated efficacy onHbA1c comparable to that of glimepiride
fter 2 years of add-on treatment withmarkedly reduced hypogly-
emia risk (2.3% vs. 18.2%) [34].
The short form 36 health survey
The short form 36 health survey (SF-36) [35–37] is a widely used,
validated generic questionnaire measuring patients’ HRQoL. It in-
cludes eight dimension scores (physical functioning, role physical,
bodily pain, general health, vitality, social functioning, role emo-
tional, and mental health) and two summary scores (Physical
Component Scale and Mental Component Scale). Dimension
scores range from 0 to 100, and summary scores are US-norm
based with a mean of 50 and an SD of 10. For all dimension and
summary scores, higher scores indicate better HRQoL. In the
study, patientswere asked to complete the SF-36 at baseline and at
weeks 24, 52, and 104. tMeasures of hypoglycemia
Objectively confirmed hypoglycemia
Patientswere considered to have a hypoglycemic eventwhen they
had plasma glucose level lower than 56 mg/dL (3.1 mmol/L) and
presence of symptoms suggestive of hypoglycemia among a list of
44 symptoms (anxiety, asthenia, dizziness, hyperhidrosis, tremor,
etc.). The number of objectively measured hypoglycemic events
was assessed both in the 1-month and 6-month periods immedi-
ately preceding SF-36 questionnaire completion.
Perceived frequency of hypoglycemia
The patients’ perceived hypoglycemia was assessed through the
single-item score “How often have you felt that your blood sugars
have been unacceptably low recently?” of the Diabetes Treatment
SatisfactionQuestionnaire (DTSQ), as defined by the authors of the
questionnaire [38,39]. The response scale for this item ranges from
0 (none of the time) to 6 (most of the time). As the SF-36, patients
were asked to complete the DTSQ in the study at baseline and at
weeks 24, 52, and 104.
Statistical analysis
Analysis of the association between hypoglycemia and HRQoL
The association between hypoglycemia and HRQoL was evaluated
by using repeated-measurements analyses. For each SF-36 score,
two repeated-measurements mixed models were performed: one
to evaluate the impact of the number of objectively confirmed
hypoglycemic events on HRQoL and one to evaluate the impact of
the perceived frequency of hypoglycemia on HRQoL. In each
model, the explained variable was the SF-36 score and the explan-
atory variables were the baseline value of the considered SF-36
score, age, sex, country, time (in weeks), and either the number of
objectively confirmed hypoglycemic events (0, 1) or the per-
ceived frequency of hypoglycemic events (continuous variable
ranging from 0 to 6). All models included data from weeks 24, 52,
and 104. The analysis was conducted on pooled treatment groups
of the intent-to-treat (ITT) population, including all subjects who
received at least one dose of the study drug and had at least one
postbaseline assessment of the primary or secondary efficacy
variableswhile ondual-therapy treatment (i.e., assessmentswhile
on rescue medication were not considered).
Statistical tests, level of significance, and software
Because of themultiplicity of tests to be performed, aweak thresh-
old for statistical significance (1%) was used for each test to de-
crease the risk of having a statistically significant test by chance.
All analyses were performedwith SAS software forWindows (Ver-
sion 9.2, SAS Institute, Inc., Cary, NC).
Results
Demographic and clinical characteristics of the study
population
The ITT population included 3059 patients among the 3118 ran-
domized patients (Fig. 1). Of patients who attended the visits, 94%,
3%, 93%, and 92% of the patients completed the SF-36 at baseline
nd at week 24, 52, and 104, respectively. Patients’ mean age was
8 years, with a majority of men and most patients coming from
estern Europe (Table 1).
Regardless of the follow-up visit, about 1% of the patients ex-
erienced at least one objectively confirmed hypoglycemic event
n a 1-month period prior to SF-36 completion and less than 6% of
he patients experienced at least one objectively confirmed hypo-
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le 2). In terms of the perceived frequency of hypoglycemic events,
bout half the patients reported having unacceptably low blood
ugars “none of the time” (48% atweek 24, 49% atweek 52, and 48%
tweek 104), while less than 2% reported having unacceptably low
lood sugars “most of the time” (2% at week 24, 1% at week 52, and
% at week 104).
Analysis of the association between hypoglycemia and
HRQoL
Regardless of time point, patients who experienced no objectively
confirmed hypoglycemic events had better HRQoL than did pa-
tients who experienced at least one (coefficients from 0.16 for
physical functioning to 6.16 for role physical in the 1-month period
prior to SF-36 completion). The only exceptions were for the gen-
eral health, mental health, and Mental Component Scale scores
Fig. 1 – Flow chart of study populations and SF-36 compl
Table 1 – Sociodemographic and clinical characteristics
of patients at baseline.
Variable ITT population
(N  3059)
Age
Mean  SD 57.6  9.2
Min–Max 19.0–74.0
Sex, n (%)
Male 1630 (53.3)
Region, n (%)
Africa 67 (2.2)
Asia 90 (2.9)
Eastern Europe 606 (19.8)
Western Europe 1452 (47.5)
North America 495 (16.2)
South America 349 (11.4)
BMI (kg/m2)
Mean  SD 31.8  5.3
Min–Max 19.8–47.8
Duration of diabetes (y)
Mean  SD 5.7  5.1
Min–Max 0.2–40.3BMI, body mass index; ITT, intent to treat.when hypoglycemia was measured 1 month prior to SF-36 com-
pletion. Results were similar when hypoglycemia wasmeasured 6
months prior to SF-36 completion (coefficients from 0.03 for men-
tal health to 3.36 for role physical) (Table 3). The association be-
tween the number of objectively confirmed hypoglycemic events
and SF-36 scores, however, was not statistically significant at the
1% threshold, both when hypoglycemia was measured 1 month
and 6 months prior to SF-36 completion. Regardless of time point,
R2 ranged from 0.19 for role emotional score to 0.45 for physical
functioning score.
Contrary to the number of objectively confirmed hypoglycemic
events, the perceived frequency of hypoglycemic events as mea-
sured by the DTSQ hypoglycemia single-item score was statisti-
cally significantly related to all SF-36 scores (P  0.001), except
physical functioning score (P  0.084) (Table 4). Patients reporting
more perceived hypoglycemic events had a worse HRQoL, with
decreases ranging from1.07 for social functioning score to0.23
for Physical Component Scale score for each 1-point increase in
DTSQ hypoglycemia score. R2 ranged from 0.26 for role emotional
score to 0.49 for physical functioning score.
Discussion
To explore whether the significant impact of hypoglycemia on
HRQoL observed in observational studies could be shown in the
monitored context of a randomized clinical trial, we analyzed the
association of hypoglycemia with HRQoL by using data resulting
from a clinical trial comparing the long-term efficacy of two treat-
ments in patients with type 2 diabetes. As no consensus exists on
how a hypoglycemic event should be defined and as the patients’
perception of hypoglycemia may differ from the actual hypogly-
cemic events experienced, both an objectively confirmed and a
patient-reported measure of hypoglycemia were used.
In our study, the association of hypoglycemia with HRQoL was
found to depend on themeasure of hypoglycemia used. The num-
ber of objectively confirmed hypoglycemic events was not found
to be significantly associated with HRQoL. In contrast, all SF-36
scores, except physical functioning, were significantly linked to
perceived hypoglycemia, with a lower HRQoL reported when the
perceived frequency of hypoglycemia rose. The significant associ-
ation between the patient-reportedmeasure of hypoglycemia and
HRQoL could be considered obvious as these are both patient-
. ITT, intent to treat; SF-36, short form 36 health survey.etedreportedmeasures. However, the objectivemeasure of hypoglyce-
at yo
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patients in a diary. Because of the nature of hypoglycemia, a def-
inition based only on clinical measures is currently not possible,
and thus patients have to be directly involved in the evaluation of
their hypoglycemic events. Therefore, it may be surprising to ob-
serve in our study such a difference between the number of objec-
tively confirmed hypoglycemic events (6% of patients) and the
patients’ perception of the frequency of hypoglycemia (half the
patients reporting unacceptably low blood sugar more than “none
of the time”). The major structural difference in the definitions of
hypoglycemia used was the measure of plasma glucose level as a
confirmation of the hypoglycemic event in addition to symptoms
reported by patients. Our results therefore suggest that blood sug-
ars considered “unacceptably low” for patients may not corre-
spond to the objective level of plasma glucose clinically estab-
lished to define a hypoglycemic event. The lack of continuous
strict plasma glucose level monitoring by patients [15,16], making
the hypoglycemic event confirmation difficult or impossible, or
measurement error of plasma glucose level by some patients
[15,40] could also explain this disparity. Apart from a potential
issue with plasma glucose level measurement, hypoglycemia-re-
Table 2 – Objectively measured hypoglycemia and patient-
Measure of hypoglycemia
Number of objectively measured hypoglycemia
One month prior to PRO questionnaire completion
0
1
Six months prior to PRO questionnaire completion
0
1
Patient-reported frequency of hypoglycemia*
0 (none of the time)
1
2
3
4
5
6 (most of the time)
DTSQ, Diabetes Treatment Satisfaction Questionnaire; PRO, patient-r
* DTSQ hypoglycemia single-item score: “How often have you felt th
Table 3 – Association between objectively measured hypog
SF-36 score Number of objectively measured hypogl
mo prior to PRO questionnaire comp
Parameter estimate
(Ref: 1 hypoglycemia)
Standard
error
t
value
Physical functioning 0.16 1.64 0.10
Role physical 6.16 3.26 1.89
Bodily pain 1.28 2.30 0.55
General health 1.50 1.53 0.99
Vitality 0.05 1.59 0.03
Social functioning 0.29 1.92 0.15
Role emotional 0.95 3.46 0.28
Mental health 2.04 1.50 1.36
PCS 0.91 0.75 1.21
MCS 0.53 1.02 0.52
HRQoL, health-related quality of life; MCS, Mental Component Scale
short form 36 health survey.lated symptoms, such as hunger, fatigue, or anxiety, are nonspe-
cific to diabetes [14,15,40]. Some patientsmay either fail to relate a
true hypoglycemia symptom to hypoglycemia and thus not mon-
itor the plasma glucose level for confirmation or incorrectly relate
a symptom to hypoglycemia and thus are not able to confirm the
hypoglycemic event with the plasma glucose level. Furthermore,
hypoglycemic symptoms can be experienced at normal blood glu-
cose level also, particularly when the blood glucose level falls rap-
idly. Because of these issues, many real hypoglycemic events are
not measured and reported. Further investigation would be
needed to better understand the discrepancy observed between
the objectively confirmed and the patient-reported measures of
hypoglycemia, but it seems clear that the patient’s feelings cannot
be neglected when evaluating hypoglycemia. Moreover, in a more
global context than the clinical trial context, physicians in clinical
practice tend tomodify diabetes therapy on the basis of symptoms
reported by patients without objective confirmation of the hypo-
glycemia event, which is generally used only for severe cases. For
example, the dose of sulfonylurea or insulin may be decreased
[17,29] or physicians may suggest patients to eat something when
experiencing dizziness or symptoms related to hypoglycemia. An-
rted frequency of hypoglycemia.
eek 24
 2780)
Week 52
(n  2627)
Week 104
(n  2307)
41 (98.6) 2599 (98.9) 2298 (99.6)
39 (1.4) 28 (1.1) 9 (0.4)
17 (94.1) 2524 (96.1) 2253 (97.7)
63 (5.9) 103 (3.9) 54 (2.3)
45 (48.4) 1287 (49.0) 1105 (47.9)
35 (15.7) 433 (16.5) 375 (16.3)
37 (8.5) 200 (7.6) 189 (8.2)
62 (5.8) 158 (6.0) 145 (6.3)
85 (3.1) 69 (2.6) 62 (2.7)
56 (2.0) 52 (2.0) 40 (1.7)
49 (1.8) 35 (1.3) 26 (1.1)
ted outcome.
ur blood sugars have been unacceptably low recently?”
mia and HRQoL scores.
ia—1
n
Number of objectively measured hypoglycemia—6
mo prior to PRO questionnaire completion
R2 Parameter estimate
(Ref: 1 hypoglycemia)
Standard
error
t
value
P R2
2 0.45 2.25 0.89 2.54 0.011 0.45
9 0.27 3.36 1.77 1.90 0.058 0.27
9 0.32 1.13 1.22 0.93 0.355 0.32
5 0.41 0.73 0.83 0.88 0.377 0.41
5 0.39 0.27 0.86 0.31 0.755 0.39
9 0.27 0.70 1.03 0.68 0.497 0.27
3 0.19 2.12 1.84 1.15 0.250 0.19
4 0.37 0.03 0.81 0.03 0.975 0.37
8 0.44 0.77 0.41 1.88 0.060 0.44
1 0.29 0.25 0.56 0.45 0.655 0.29
, Physical Component Scale; PRO, patient-reported outcome; SF-36,repo
W
(n
27
26
1
13
4
2
1
eporlyce
ycem
letio
P
0.92
0.05
0.57
0.32
0.97
0.87
0.78
0.17
0.22
0.60
; PCS
u
a
p
r
s
a
y
t
t
d
t
h
T
b
H
a
a
1
o
a
g
p
t
p
s
o
o
o
H
p
h
h
q
t
o
r
h
t
w
p
a
t
p
p
p
o
s
s
a
u
D
a
d
h
at yo
1040 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 3 6 – 1 0 4 1other key aspect of the patient perception of diabetes is fear of
hypoglycemia, which has been shown to have major implications
on the disease management [41]. Therefore, patients’ feelings are
ofmajor interest not only because they enable thewhole benefit of
a new treatment to be evaluated in clinical trials but also because
they can serve as supportive information for key medical deci-
sions in clinical practice.
The significant negative impact of hypoglycemia onHRQoL has
often been demonstrated in the context of observational studies.
In our study, similar findings were observed when hypoglycemia
was measured through patients’ perception of the frequency of
hypoglycemia. Important differences have to be highlighted be-
tween previous studies and our study. Onemajor difference lies in
the definition of hypoglycemia. In previous studies, hypoglycemia
was often measured in terms of symptoms reported by patients
with no objective confirmation of hypoglycemic events by using
measures such as the plasma glucose level [20,31,32], while we
sed both an objectively confirmedmeasure of hypoglycemia and
patient-reported frequency of hypoglycemia. Moreover, the time
eriod over which hypoglycemia was measured and the recall pe-
iod of HRQoL questionnaires were not always concordant in ob-
ervational studies. InAlvarezGuisasola et al. [31] and Jermendy et
l. [33], hypoglycemia symptoms were measured in the previous
ear,whileHRQoLwas evaluated “today” by using the EQ-5Dques-
ionnaire; in Davis et al. [32], the recall period was 3 months for
hypoglycemia symptoms and 1 month and “today” for SF-36 and
EuroQol five-dimensional questionnaire, respectively; in Marrett
et al. [20], the recall period was 6 months for hypoglycemia symp-
oms and “today” for HRQoL as measured by the EuroQol five-
imensional questionnaire. In our study, we paid particular atten-
ion to this issue as it is of major importance that patients assess
ypoglycemia and HRQoL with the same time period as reference.
o reflect the same time interval, we evaluated the association
etween the patient-reported frequency of hypoglycemia and
RQoL using DTSQ and SF-36 completed at the same time point,
nd objectively confirmed hypoglycemic events weremeasured in
1-month period prior to SF-36 completion as the SF-36 uses a
-month recall period. As a very few hypoglycemic events were
bserved over a 1-month period (about 1% of the patients), the
nalysis was also conducted by using objectively confirmed hypo-
lycemic eventsmeasured in a 6-month period prior to SF-36 com-
letion. The analysis of the association betweenHRQoL and objec-
ively confirmed hypoglycemic events measured in a 1-month
eriod and a 6-month period resulted in similar findings.
Because of the particular context of a randomized clinical trial,
Table 4 – Association between patient-reported frequency
SF-36 score Patien
Parameter
estimate
Standa
error
Physical functioning 0.23 0.13
Role physical 0.85 0.27
Bodily pain 0.87 0.19
General health 0.78 0.12
Vitality 0.42 0.13
Social functioning 1.07 0.16
Role emotional 1.06 0.28
Mental health 0.53 0.12
PCS 0.23 0.06
MCS 0.23 0.09
PCS, physical component scale; MCS, mental component scale.
In bold, p-value  0.01.
* DTSQ hypoglycemia single-item score: “How often have you felt thome limitations to our study cannot be ruled out. In particular,ne could argue that results could be driven by the potential effect
f each treatment on either hypoglycemic events or HRQoL. Our
bjective, however, was to analyze the impact of hypoglycemia on
RQoL independently of the treatment and its impact, as done in
revious observational studies, to obtain a general overview of
ow hypoglycemia can affect patients’ perception of their own
ealth status. Moreover, the generalizability of our results may be
uestioned as our study is, to our knowledge, the first evaluating
he hypoglycemia-HRQoL association by using different measures
f hypoglycemia in the context of a randomized clinical trial. Our
esults should thus be confirmed in other clinical trials. Finally, it
as to be noted that our analysis was conducted without differen-
iation betweenmild, moderate, and severe hypoglycemia events,
hich may be considered a substantial limitation from a clinical
erspective. The use of patient-reportedmeasures, however, aims
t assessing hypoglycemia as perceived by patients. Patients can
hus report any hypoglycemic event they have the feeling to ex-
erience, regardless of the clinical degree of these events, and the
atient perspective can thus be fully evaluated, in terms of both
erceived hypoglycemia and its impact on HRQoL.
In conclusion, showing direct impact of diabetes treatment
n HRQoL is often an issue in diabetes clinical trials while mea-
uring the patients’ perspective is of major importance to en-
ure that improving clinical outcomes is perceived by patients
s beneficial for their daily lives. Our results demonstrated that
sing a patient-reported measure of hypoglycemia such as the
TSQ-perceived frequency of hypoglycemia item would be an
dded value to demonstrate the potential indirect benefit of a
iabetes treatment on patients’ HRQoL through the burden of
ypoglycemia.
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